Status:
COMPLETED
Prostate Cancer Antigen 3 (PCA-3) Gene Project
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Prostate Cancer
Benign Prostatic Hypertrophy
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Nowadays, prostate cancer screening is largely widespread although it is not recommended yet. This screening includes primarily digital rectal examination and PSA. Recently, a new specific genetic ma...
Detailed Description
Nowadays, prostate cancer screening is largely widespread although it is not recommended yet. This screening includes primarily digital rectal examination and PSA. The main drawback is the poor PSA s...
Eligibility Criteria
Inclusion
- Patients operated for a prostate cancer or a benign prostatic hypertrophy
- Patients not in state of emergency
Exclusion
- Patients with an urinary infection proved bacteriologically
- Patients with a vesical malign disease
- Patients in state of emergency
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01177436
Start Date
September 1 2009
End Date
December 1 2011
Last Update
August 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique - Hôpitaux de Marseille
Marseille, France